kombinierten Radio-Chemotherapie mit dosisgesteigerter Strahlentherapie
Die Strahlentherapie mit hoher Dosis hat ähnliche Ergebnisse wie die Standarddosis aber mehr Nebenwirkungen Grad 3.
Daher Standarddosis empfohlen.
| Studie | Autor | Chemotherapie | Dosis | 3a-OS | Rezidiv | Metastasen | |
| simultan | Induktion | ||||||
| SAKK 76/02 | Ruhstaller 2010 (1) | CisP/Doce | CisP/Doce | 59,4Gy | 29% | 71% | 18% |
| Niigata | Sasamoto 2007 (2) | CisP/5-FU | - | 60-70Gy | 32% | 51% | 25% |
| FFCD 9102 | Bedenne 2007 (3) | CisP/VP16 | CisP/5-FU | 66Gy | 28% | 43% | 29% |
| GECSG | Stahl 2005 (4) | CisP/VP16 | CisP/5-FU/Leu/VP16 | 65Gy | 25% | 55% | 18% |
| Shanghai | Zhao 2005 (5) | CisP/5-FU | - | 68,4Gy | 40% | 26% | 22% |
| INT0123 | Minsky 2002 (6) | CisP/5-FU | - | 64,8Gy | 23% | 50% | 9% |
| Tours | Calais 1997 (7) | CisP/5-FU/MMC | - | 60Gy + AL | 27% | 35% | 26% |
| Lyon | Zenone 1992 (8) | CisP/5-FU | CisP/5-FU | 64Gy | 20% | 38% | 11% |
Teil von
Intense therapy in patients with locally advanced esophageal cancer beyond hopr for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02).
Onkologie 33(2010):222-8
2.)Sasamoto R, Sakai K, Inakoshi H et al.:
Long-term results of chemoradiotherapy for locally advanced esophageal cancer, using daily low-dose 5-fluorouracil and cis-diammine-dichloro-platinum (CDDP).
Int J Clin Oncol. 12(2007):25-30
3.) Bedenne L, Michel P, Bouche O et al.:
Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.
JCO 25(2007):1160-8
4.) Stahl M, Stuschke M, Lehmann N et al.:
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
JCO 23(2005):2310-7
5.) Zhao K, Shi X, Jiang G et al.:
Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: a phase III randomized study.
IJROBP 62(2005):1014-20
6.) Minsky BC, Pajak TF, Ginsberg RJ et al.:
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.
JCO 20(2002):1167-74
7.) Calais G, Dorval E, Louisot P et al.:
Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for Stages IIB and III esophageal carcinoma: results of a pilot study.
J Radiat Oncol Biol Phys. 38(1997):769-75.
8.) Zenone T, Romestaing P, Lambert R, Gerard JP.:
Curative non-surgical combined treatment of squamous cell carcinoma of the oesophagus.
Eur J Cancer. 28A(1992):1380-6
9.) Pöttgen C, Stuschke M:
Chemoradiotherapie beim fortgeschrittenen Ösophaguskarzinom: Zielvolumendefinition nach PET/CT-Planung und dosisgesteigerte Radiochemotherapie.
Symposium „Klinische Onkologie“ Düsseldorf 2011/2012
10.) Gebski J, Burmeister B, Smithers BM et al.:
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a metaanalysis.
Lancet Oncol 2007;8:226-34.
11.) Wang X et al.:
High versus standard radiation dose of definitive concurrent chemoradiotherapy for esophageal cancer: A systematic review and meta-analysis of randomized clinical trials.
Radiotherapy and Oncology 2023;180:109463
